Transition Rate from EGFR-TKI to Cytotoxic Chemotherapy Patients with EGFR Mutation-positive Lung Adenocarcinoma

Kawaguchi, Y; Okano, T; Kakihana, M; Kajiwara, N; Ohira, T; Ikeda, N

Okano, T (reprint author), Tokyo Med Univ, Dept Gen Thorac Surg, Shinjuku Ku, 6 Chome 7-1 Nishishinjuku, Tokyo 1600023, Japan.

ANTICANCER RESEARCH, 2018; 38 (5): 3127

Abstract

Background/Aim: The transition rate from first-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) to cytotoxic chemotherapy ......

Full Text Link